Want to see SE:EXPRS2 full AI Analyst Report?
ExpreS2ion Biotech Holding AB (EXPRS2) Stock Statistics & Valuation Metrics
Total Valuation
ExpreS2ion Biotech Holding AB has a market cap or net worth of SEK 36.86M. The enterprise value is SEK 22.17M.
- Market Cap
- SEK 36.86M
- Enterprise Value
- SEK 22.17M
Share Statistics
ExpreS2ion Biotech Holding AB has 39,468,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 39,468,700
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
ExpreS2ion Biotech Holding AB’s return on equity (ROE) is -1.07 and return on invested capital (ROIC) is -121.91%.
- Return on Equity (ROE)
- -1.07
- Return on Assets (ROA)
- -0.58
- Return on Invested Capital (ROIC)
- -121.91%
- Return on Capital Employed (ROCE)
- -1.43
- Revenue Per Employee
- 192.47K
- Profits Per Employee
- -2.00M
- Employee Count
- 19
- Asset Turnover
- 0.06
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ExpreS2ion Biotech Holding AB is -0.14. ExpreS2ion Biotech Holding AB’s PEG ratio is -0.00.
- PE Ratio
- -0.14
- PS Ratio
- 0.62
- PB Ratio
- 0.81
- Price to FCF
- -0.07
- Price to Operating Cash Flow
- -0.70
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, ExpreS2ion Biotech Holding AB had revenue of 3.66M and earned -38.09M in profits. Earnings per share was -13.39.
- Revenue
- 3.66M
- Gross Profit
- -42.84M
- Operating Income
- -52.82M
- Pretax Income
- -44.18M
- Net Income
- -38.09M
- EBITDA
- -51.35M
- Earnings Per Share (EPS)
- -13.39
Cash Flow
In the last 12 months, operating cash flow was -47.77M and capital expenditures 38.00M, giving a free cash flow of -35.27M billion.
- Operating Cash Flow
- -47.77M
- Free Cash Flow
- -35.27M
- Free Cash Flow per Share
- -0.98
Dividends & Yields
ExpreS2ion Biotech Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1480.12%
- Earnings Yield
- -106.78%
Stock Price Statistics
- Beta
- 1.19
- 52-Week Price Change
- -84.87%
- 50-Day Moving Average
- 1.19
- 200-Day Moving Average
- 2.13
- Relative Strength Index (RSI)
- 32.21
- Average Volume (3m)
- 125.59K
Important Dates
ExpreS2ion Biotech Holding AB upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
ExpreS2ion Biotech Holding AB as a current ratio of 2.04, with Debt / Equity ratio of 6.18%
- Current Ratio
- 2.04
- Quick Ratio
- 2.04
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 0.88
- Interest Coverage Ratio
- -117.12
Taxes
In the past 12 months, ExpreS2ion Biotech Holding AB has paid -6.09M in taxes.
- Income Tax
- -6.09M
- Effective Tax Rate
- 0.14
Enterprise Valuation
ExpreS2ion Biotech Holding AB EV to EBITDA ratio is 0.50, with an EV/FCF ratio of 0.87.
- EV to Sales
- -7.96
- EV to EBITDA
- 0.50
- EV to Free Cash Flow
- 0.87
- EV to Operating Cash Flow
- 0.64
Balance Sheet
ExpreS2ion Biotech Holding AB has SEK 34.38M in cash and marketable securities with SEK 1.45M in debt, giving a net cash position of SEK 32.93M billion.
- Cash & Marketable Securities
- SEK 34.38M
- Total Debt
- SEK 1.45M
- Net Cash
- SEK 32.93M
- Net Cash Per Share
- SEK 0.83
- Tangible Book Value Per Share
- SEK 1.12
Margins
Gross margin is -1056.01%, with operating margin of -1674.43%, and net profit margin of -935.91%.
- Gross Margin
- -1056.01%
- Operating Margin
- -1674.43%
- Pretax Margin
- -1135.39%
- Net Profit Margin
- -935.91%
- EBITDA Margin
- -1591.58%
- EBIT Margin
- -1623.33%
Analyst Forecast
The average price target for ExpreS2ion Biotech Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.29%
- EPS Growth Forecast
- 55.71%
Scores
- Smart Score
- ―
- AI Score
- 41